Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serelaxin versus standard of care in acute heart failure
2013-002513-35Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Acute Heart Failure (AHF) comparing Serelaxin with Standard of care (2 arms). Primary endpoint: Time to in-hospital worsening of heart failure or death through Day 5. Started Oct 2013; status: terminated.
02
Drugs
serelaxin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2013-002513-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002513-35.